These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32851872)

  • 41. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
    Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
    Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluating longitudinal therapy effects via the North Star Ambulatory Assessment.
    McDonald CM; Wei LJ; Flanigan KM; Elfring G; Trifillis P; Muntoni F; ;
    Muscle Nerve; 2021 Nov; 64(5):614-619. PubMed ID: 34383312
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Symptoms and impacts of ambulatory nonsense mutation Duchenne muscular dystrophy: a qualitative study and the development of a patient-centred conceptual model.
    Williams K; Davidson I; Rance M; Boehnke A; Buesch K; Acaster S
    J Patient Rep Outcomes; 2021 Aug; 5(1):75. PubMed ID: 34420127
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness of pharmacological treatments in Duchenne muscular dystrophy: a protocol for a systematic review and meta-analysis.
    Pascual Morena C; Martinez-Vizcaino V; Álvarez-Bueno C; Fernández Rodríguez R; Jiménez López E; Torres-Costoso AI; Cavero-Redondo I
    BMJ Open; 2019 Sep; 9(9):e029341. PubMed ID: 31494609
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations.
    Wagner KR; Hamed S; Hadley DW; Gropman AL; Burstein AH; Escolar DM; Hoffman EP; Fischbeck KH
    Ann Neurol; 2001 Jun; 49(6):706-11. PubMed ID: 11409421
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A qualitative study on the impact of caring for an ambulatory individual with nonsense mutation Duchenne muscular dystrophy.
    Williams K; Davidson I; Rance M; Buesch K; Acaster S
    J Patient Rep Outcomes; 2021 Aug; 5(1):71. PubMed ID: 34374872
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up.
    Dori A; Guglieri M; Scutifero M; Passamano L; Trabacca A; Politano L
    Acta Myol; 2021 Dec; 40(4):152-157. PubMed ID: 35047755
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Studies point way to new therapeutic prospects for muscular dystrophy.
    Kuehn BM
    JAMA; 2007 Sep; 298(12):1385-6. PubMed ID: 17895449
    [No Abstract]   [Full Text] [Related]  

  • 49. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status.
    McDonald CM; Marden JR; Shieh PB; Wong BL; Lane H; Zhang A; Nguyen H; Frean M; Trifillis P; Koladicz K; Signorovitch J
    J Comp Eff Res; 2023 Apr; 12(4):e220190. PubMed ID: 36749302
    [No Abstract]   [Full Text] [Related]  

  • 50. Long term treatment with ataluren-the Swedish experience.
    Michael E; Sofou K; Wahlgren L; Kroksmark AK; Tulinius M
    BMC Musculoskelet Disord; 2021 Sep; 22(1):837. PubMed ID: 34592975
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.
    Sermet-Gaudelus I; Boeck KD; Casimir GJ; Vermeulen F; Leal T; Mogenet A; Roussel D; Fritsch J; Hanssens L; Hirawat S; Miller NL; Constantine S; Reha A; Ajayi T; Elfring GL; Miller LL
    Am J Respir Crit Care Med; 2010 Nov; 182(10):1262-72. PubMed ID: 20622033
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.
    Shimizu-Motohashi Y; Murakami T; Kimura E; Komaki H; Watanabe N
    Orphanet J Rare Dis; 2018 Jun; 13(1):93. PubMed ID: 29907124
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy.
    Victor RG; Sweeney HL; Finkel R; McDonald CM; Byrne B; Eagle M; Goemans N; Vandenborne K; Dubrovsky AL; Topaloglu H; Miceli MC; Furlong P; Landry J; Elashoff R; Cox D;
    Neurology; 2017 Oct; 89(17):1811-1820. PubMed ID: 28972192
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early Cost-Utility Analysis of Ataluren and Eteplirsen in the Treatment of Duchenne Muscular Dystrophy in Egypt.
    Shehata Z; Metry A; Rabea H; El Sherif R; Abdelrahim M; Dawoud D
    Value Health Reg Issues; 2023 Nov; 38():109-117. PubMed ID: 37862859
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The relationship between deficit in digit span and genotype in nonsense mutation Duchenne muscular dystrophy.
    Thangarajh M; Elfring GL; Trifillis P; McIntosh J; Peltz SW;
    Neurology; 2018 Sep; 91(13):e1215-e1219. PubMed ID: 30135256
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy.
    Mah JK
    Methods Mol Biol; 2018; 1687():3-17. PubMed ID: 29067652
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expectations and experiences of investigators and parents involved in a clinical trial for Duchenne/Becker muscular dystrophy.
    Peay HL; Tibben A; Fisher T; Brenna E; Biesecker BB
    Clin Trials; 2014 Feb; 11(1):77-85. PubMed ID: 24311736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.